Canada· CA-DIN-02359499
MOVIPREP
A macrogol, kombinationen product containing sodium sulfate anhydrous + ascorbic acid + sodium chloride + sodium ascorbate, registered in Canada by ARALEZ PHARMACEUTICALS CANADA INC. The same ATC class is registered in 11 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Macrogol, kombinationen is registered in 11 of 19 countries.
Countries holding a registration under ATC A06AD65 (macrogol, kombinationen), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 7 of them publish a price we can compare per daily dose
Macrogol, kombinationen · ATC A06AD65
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- SODIUM SULFATE ANHYDROUS + ASCORBIC ACID + SODIUM CHLORIDE + SODIUM ASCORBATE
- Manufacturer
- ARALEZ PHARMACEUTICALS CANADA INC
- Country
- Canada (CA)
- ATC code
- A06AD65
- ATC class
- Macrogol, Kombinationen
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
449 interactions on record for macrogol, kombinationen.
Graded by severity as the source publishes them — 37 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Macrogol, kombinationen · interactions on record
449 records
- 37 severe
- 411 moderate
- 1 minor
Most severe, free to view
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- QuinidineC01BA01severe
- ProcainamideC01BA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under A06AD65
Macrogol, kombinationen, as other registers publish it.
- NorwayAbdominOrifarm Healthcare A/S
- NorwayAbdominOrifarm Healthcare A/S
- DenmarkAbdomin CitrusOrifarm Healthcare A/S
- DenmarkAbdomin Junior NeutralOrifarm Healthcare A/S
- DenmarkAbdomin NeutralOrifarm Healthcare A/S
- PolandAuroGoAurovitas Pharma Polska Sp. z o.o.
- NetherlandsBENLAXID 13,7 g poeder voor drankItalfarmaco, S.A.
- NetherlandsBENLAXID 6,9 g poeder voor drankItalfarmaco, S.A.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e04609f5-e802-46ae-bbe1-726c13e81d0c GET /v1/drugs/e04609f5-e802-46ae-bbe1-726c13e81d0c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02359499",
"form": "POWDER FOR SOLUTION",
"class": "Human",
"routes": [
"ORAL"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "A06AD65",
"schedule": [
"Ethical"
],
"drug_code": "84451",
"strengths": [
"7.5 G",
"4.7 G",
"2.691 G",
"5.9 G",
"100 G",
"1.015 G"
],
"ahfs_class": null,
"substances": [
"SODIUM SULFATE ANHYDROUS",
"ASCORBIC ACID",
"SODIUM CHLORIDE",
"SODIUM ASCORBATE",
"POLYETHYLENE GLYCOL 3350",
"POTASSIUM CHLORIDE"
],
"product_categorization": null
}See everything about macrogol, kombinationen.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.